

# Comparative study of the efficacy of "short" and "long" duration levofloxacin-rifampicin combination therapy in the treatment of early postoperative and haemotogenous staphylococcal prosthetic joint infection

<b>Submission date</b> 25/02/2011	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 04/08/2011	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 04/08/2011	<b>Condition category</b> Infections and Infestations	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Javier Ariza

**Contact details**  
Hospital Universitario de Bellvitge  
Servicio de Enf. Infecciosas  
c/ Feixa Llarga s/n  
L'Hospitalet de Llobregat  
Barcelona  
Spain  
08907  
jariza@bellvitgehospital.cat

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

ClinicalTrials.gov number

Secondary identifying numbers

LR-07

## Study information

### Scientific Title

Comparative study of the efficacy of "short" and "long" duration levofloxacin-rifampicin combination therapy in the treatment of early postoperative and haematogenous staphylococcal prosthetic joint infection: a phase IV, multicentre, open trial

### Study objectives

In the early postoperative and haematogenous staphylococcal prosthetic joint infection with stable implant, treated with surgical debridement and the antibiotic combination of rifampicin and levofloxacin, a short length of therapy of 8 weeks is non inferior to a longer standard therapy of 3 to 6 months (3 in hip prosthesis, and 6 in knee prosthesis)

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Ethic Committee for Clinical Research (CEIC - Comité Ético de Investigación Clínica. Hospital Universitario de Bellvitge. c/ Feixa Llarga s/n. 08907 L'Hospitalet de Llobregat - Barcelona, Spain) approved on 6th November 2008

### Study design

Phase IV multicentre open trial

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Hospital

### Study type(s)

Treatment

### Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

### Health condition(s) or problem(s) studied

Prosthetic joint infection

### Interventions

In the same clinical setting of early postoperative or haematogenous staphylococcal prosthetic joint infection treated with surgical debridement. The intervention consists of administering the same antimicrobial therapy for different lengths of therapy: short duration of 8 weeks vs longer therapy of 3-6 months

## **Intervention Type**

Drug

## **Phase**

Phase IV

## **Drug/device/biological/vaccine name(s)**

Levofloxacin, rifampicin

## **Primary outcome measure**

To assess the efficacy of a treatment consisting in early surgical debridement and antimicrobial therapy with an oral combination of rifampin and levofloxacin during either 8 weeks (Short schedule group) or 3 (hip prosthesis) to 6 (knee prosthesis) months (Long schedule group; standard schedule), in the early-postoperative and haematogenous prosthesis joint infection of staphylococcal etiology (Staphylococcus aureus and Coagulase-negative Staphylococcus)

## **Secondary outcome measures**

1. Success of therapy: absence of fever, inflammatory signs or fistula and absence of radiographic prosthesis loosening during the follow-up (12 months)
2. Failure, defined as:
  - 2.1. Persistence of the infection either during treatment (persistence of inflammatory symptoms and signs which lead to the removal of the prosthesis) or at the end of treatment [(symptoms and signs suggestive of infection, with positive cultures (either from surgical or clinically significant samples)). A high value of C-reactive protein at the end of treatment, without clinical signs of relapse or persistence, is not considered criteria of failure by itself.
  - 2.2. Relapse of the infection: initial remission of inflammatory symptoms and signs with posterior reappearance and positive cultures of the same microorganism responsible of the infection from surgical or clinically significant samples.
  - 2.3. Reinfection: initial remission of inflammatory symptoms and signs with posterior reappearance and positive cultures of a different microorganism from surgical or clinically significant samples.In cases of persistence or relapse, evaluation of possible development of resistance to either rifampicin or quinolones will be performed.
3. Aseptic prosthesis loosening during follow-up, with no clinical evidence of infection and negative cultures
4. Adverse events. All adverse events will be collected, and the possible relation with the antibiotics will be evaluated. Serious adverse events will be reported to authorities, according to the law (Real Decreto 223/2004). Especial attention will be given to the following adverse events:
  - 4.1. Gastrointestinal adverse events: vomiting, nausea, etc
  - 4.2. Rise in liver enzymes
  - 4.3. Flu-like syndrome secondary to rifampicin (head-ache, chills or rigors, arthralgias, myalgias)
  - 4.4. Lupus-like syndrome secondary to rifampicin
  - 4.5. Myopathy or tendinitis secondary to levofloxacin

**Overall study start date**

13/04/2009

**Completion date**

13/04/2013

## **Eligibility**

**Key inclusion criteria**

1. Diagnosis of prosthesis joint infection: fever, local pain, inflammatory signs or purulent exudate in the surgical wound and/or purulent macroscopic exudate during the debridement surgery. Prosthesis joint infection will be considered early-postoperative if symptoms and signs begin in the first 30 days after the placement of the prosthesis. It will be considered haematogenous when the clinical picture is acute and/or it develops in the setting of bacteremia or concomitant to other distant infection.
2. Diagnosis of staphylococcal etiology: Staphylococcus sp must be isolated from reliable samples, such as blood cultures or purulent exudate obtained during surgery or by arthrocentesis. Polymicrobial cases will be accepted if it is not necessary to add more antibiotics with anti-staphylococcal activity to the oral combination of rifampicin and levofloxacin.

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Both

**Target number of participants**

195

**Key exclusion criteria**

1. Age less than 18 years
2. Pregnancy or breastfeeding
3. Women who may become pregnant in whom methods of contraception cannot be guaranteed during the period of antibiotic therapy
4. Life-expectancy less than 6 months
5. Unwillingness to participate in the study or to give written-informed consent
6. Unwillingness to avoid the use of contact lenses during the period of antibiotic therapy
7. Reasonable doubts about the patients treatment observance
8. Allergy or intolerance to quinolones and/or rifampicin which lead to the antimicrobial(s) withdrawal. Prosthesis joint infection by quinolones and/or rifampicin resistance
9. Administration of antibiotics with anti-staphylococcal activity different from rifampicin or levofloxacin for more than 7 days, during the period of study or during the follow-up
10. Delay in performing the surgical debridement of the prosthesis infection of 21 or more days, counting from the beginning of symptoms and signs of infection
11. Radiographic signs of prosthesis loosening in simple X-ray
12. Prosthesis removal during surgery

**Date of first enrolment**

13/04/2009

**Date of final enrolment**

13/04/2013

## **Locations**

**Countries of recruitment**

Spain

**Study participating centre**

Hospital Universitario de Bellvitge

Barcelona

Spain

08907

## **Sponsor information**

**Organisation**

University Hospital of Bellvitge (Hospital Universitario de Bellvitge) (Spain)

**Sponsor details**

Hospital Universitario de Bellvitge

c/o Dr. Javier Ariza

Servicio de Enf. Infecciosas

c/ Feixa Llarga s/n

L'Hospitalet de Llobregat

Barcelona

Spain

08907

jariza@bellvitgehospital.cat

**Sponsor type**

Hospital/treatment centre

**ROR**

<https://ror.org/00epner96>

## **Funder(s)**

**Funder type**

Government

**Funder Name**

Carlos III Health Institute (Instituto de Salud Carlos III) (Spain) - Health Research Fund (Fondo de Investigaciones Sanitarias [FIS]) - Ministry of Health ref: Expte EC/08/00113

**Results and Publications****Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration